Associated Genetic Biomarkers
EED Loss is present in 0.10% of AACR GENIE cases, with chronic lymphocytic leukemia/small lymphocytic lymphoma, neuroblastoma, breast invasive ductal carcinoma, malignant peripheral nerve sheath tumor, and breast invasive lobular carcinoma having the greatest prevalence .
EED Loss serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains EED Loss as an inclusion criterion, 1 is phase 2 (1 open).
Trials with EED Loss in the inclusion eligibility criteria most commonly target malignant peripheral nerve sheath tumor .
Decitabine and cedazuridine is the most frequent therapy in trials with EED Loss as an inclusion criteria .
Significance of EED Loss in Diseases
Malignant Peripheral Nerve Sheath Tumor +
EED is altered in 11.11% of malignant peripheral nerve sheath tumor patients with EED Loss present in 3.61% of all malignant peripheral nerve sheath tumor patients .
EED Loss is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains EED Loss and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.